Colon cancer has long been considered a disease that comes with old age. However, the trend line of disease has been moving in the wrong direction for years, in a population we long assumed wasn’t at risk. And while researchers continue to investigate the why, there's a parallel conversation we aren't having nearly enough. One that has nothing to do with science, and everything to do with operations.
As we confront the sobering statistics and growing impact of colorectal cancer, it's clear that more education about the various options for testing is needed to increase screening rates across the U.S.
How to turn analytics into actual policy outcomes.
The Silicon Valley startup has developed a cloud-based platform for recording colonoscopies. It allows gastroenterologists to start and stop recording the procedure with the push of a button.
A Belgian startup may offer an alternative to screening colonoscopies – VolitionRx is reporting its single-drop blood test can diagnose 84 percent of colorectal cancers of all stages, with 78 percent specificity. The company just raised $1.1 million. Data from its 938-subject sample of a 4,800 pilot study in Denmark demonstrate the company’s NuQ diagnostic platform is fairly […]